Hone AJ , McIntosh JM .

R35 GM136430 NIGMS NIH HHS

	FIGURE 1. Ligand-binding promotes function of human α10 nAChRs expressed in X. laevis oocytes. Oocytes were injected with cRNA encoding human α10 subunits and treated for 3 days with frog saline or saline containing the indicated compounds then assessed by voltage-clamp electrophysiology for functional responses to acetylcholine (ACh; 1 mM). (A) Scatter plots of the data obtained under the indicated treatment conditions. (B) expanded data for oocytes injected with water, untreated (saline incubation only), and treated with saline containing ACh (5 mM) or α-Bgtx (1 μM). The noise amplitude recorded from oocytes injected with water was −1.7 ± 0.5 nA (n = 9). Oocytes injected with water containing cRNA for α10 subunits responded to ACh with current amplitudes that were −3.6 ± 2.8 nA (n = 32). Oocytes treated with STR (20 μM), BRU (20 μM) or MLA (20 μM) responded to ACh with current amplitudes that were significantly larger than those from controls; −735 ± 545 nA with a range of −76 to −2,378 nA (n = 28) for STR, −302 ± 225 nA with a range of −50 to −888 nA (n = 13) for BRU, and −813 ± 641 nA with a range of −146 to −2,443 nA (n = 16) for MLA. Oocytes treated with α-Bgtx, ACh, Cho, or Nic were −39 ± 21 nA (n = 9), −17 ± 11 nA (n = 13), −3.7 ± 1.5 nA (n = 10), and −6.0 ± 6.2 nA (n = 15), respectively. Currents from oocytes treated with α-Bgtx were slightly larger than saline controls, but there were no significant differences in current amplitudes recorded from oocytes treated with ACh, Cho or Nic compared to saline controls. (D) Example of a current trace from a control oocyte injected with water and stimulated with ACh. (D–K) Current traces from oocytes treated with the indicated ligand. The −5 nA scale bar applies to traces in (C,D), and (H–K) and the −150 nA scale bar applies to (E–G). The “±” and error bars indicate. The “n” indicates the number of oocytes obtained from 15 donors.
	FIGURE 2. Human α10 nAChR currents are smaller in the presence of Ba2+ compared to those in Ca2+. Oocytes were injected with cRNA encoding human α10 subunits and treated for 36 h with frog saline containing STR (20 μM) and assessed by voltage-clamp electrophysiology for functional responses to acetylcholine (ACh; 1 mM) in the presence of calcium or barium. (A) Current traces from an oocyte perfused with saline containing calcium (1.8 mM) then with saline where calcium was replaced with equimolar barium. The responses in the presence of barium were smaller than those recorded in the presence of calcium (−373 ± 273 nA vs. −301 ± 225 nA, respectively; n = 11). The experiment was repeated with sibling oocytes that had been incubated with 1 µM actinomycin-D (Actino-D) to inhibit RNA transcription. (B) Current traces from an oocyte treated with Actino-D and perfused with saline containing calcium (1.8 mM) then with saline where calcium was replaced with equimolar barium. (C) No differences in response amplitudes in the presence of calcium compared those recorded in the presence of barium (−186 ± 96 nA vs. −164 ± 96 nA, respectively; n = 14) were found in oocytes treated with Actino-D. The current traces in (A) and (B) are shown with the 30 s the interpulse intervals reduced to 5 s for brevity and the scale bar in (A) also applies to (B). The “±” and error bars indicate SD. The “n” indicates the number of oocytes obtained from two donors.
	FIGURE 3. Strychnine, BRU, and MLA produce differential effects on α10 nAChR functionality. X. laevis oocytes were injected with cRNA encoding human α10 subunits and treated for 3 days in frog saline containing MLA (20 μM), STR (20 μM), or BRU (20 μM) and assessed by voltage-clamp electrophysiology. (A) Current traces from an oocyte treated with MLA and stimulated with acetylcholine (ACh; 1 mM) immediately after being placed in the recording chamber. (B) Current traces from an oocyte treated with STR and stimulated with ACh immediately after being placed in the recording chamber. (C) The calculated plateau values indicated that currents from oocytes treated with MLA would decay to 12 (11–13) % (n = 8) of initial current amplitudes. (D) Similarly, currents from oocytes treated with BRU would decay to 15 (13–17) % (n = 8) of initial values. By contrast, oocytes treated with STR decayed to only 74 (72–76) % (n = 13) of initial values. Representative current traces for MLA and STR are shown with the 30 s interpulse intervals reduced to 5 s for brevity. The error bars in (C) and (D) indicate SD and values in parenthesis indicate 95% CI. The “n” indicates the number of oocytes obtained from five donors.
	FIGURE 4. Currents evoked by ACh are enhanced by acute exposure to STR, BRU, or MLA. X. laevis oocytes were injected with cRNA encoding human α10 subunits and incubated for 3–4 days with frog saline then assessed by voltage-clamp electrophysiology. (A) Oocytes incubated in saline were stimulated with acetylcholine (ACh; 1 mM) and acutely perfused with STR (20 μM) for 30 min. The responses to ACh before and after perfusion with STR were −6.0 ± 2.9 nA and −294 ± 149 nA (n = 7), respectively. The traces in red indicate control responses obtained prior to perfusion with STR. Current traces are shown with the 30 s interpulse intervals reduced to 5 s for brevity. (B) Methyllycaconitine enhanced responses to ACh in a concentration-dependent manner. Oocytes were stimulated with ACh and the current amplitudes monitored for changes in amplitude during continuous perfusion with MLA at the indicated concentrations. The responses in the presence of MLA (10 nM through 100 μM) were 108 ± 6%, 286 ± 68%, 431 ± 235%, 173 ± 119%, and 90 ± 33% (n = 5), respectively, of control values; responses in the presence of 1 μM were significantly larger than those in the presence of 10 nM MLA. (C) Brucine enhanced responses to ACh in a concentration-dependent manner. Oocytes were stimulated with ACh and the current amplitudes monitored for changes in amplitude during continuous perfusion with BRU at the indicated concentrations. The responses in the presence of BRU (100 nM through 300 μM) were 87 ± 16%, 246 ± 74%, 371 ± 101%, 260 ± 102%, and 168 ± 73% (n = 5), respectively, of control values; responses in the presence of 10 μM were significantly larger than those in the presence of 100 nM BRU. (D) Acetylcholine responses in oocytes treated with MLA were enhanced by acute perfusion with STR. Oocytes were stimulated with ACh and the current amplitudes monitored for changes in amplitude during continuous perfusion with STR at the indicated concentrations. The responses in the presence of STR (10 nM through 100 μM) were 92 ± 14%, 157 ± 31%, 278 ± 72%, 186 ± 51%, and 51 ± 17% (n = 4), respectively, of control values; responses in the presence of 1 μM were significantly larger than those in the presence of 10 nM STR. (E) Acetylcholine responses in oocytes treated with STR were inhibited by acute perfusion of STR. The responses in the presence of STR (10 nM through 100 μM) were 97 ± 2%, 91 ± 8%, 92 ± 12%, 71 ± 18%, and 12 ± 8% (n = 5), respectively, of control values; responses in the presence of 1 μM were no different than those in the presence of 10 nM STR. The estimated IC50 for STR was determined to be 20.2 (13.8–29.5) μM. The error bars and the “±” and indicate SD and values in parentheses indicate the 95% CI; “n” indicates the number of oocytes obtained from four donors; ns is not significant. Oocytes in (B,D) were incubated with saline containing MLA (20 μM), those in (C) with BRU (20 μM), and in (E) with STR (20 μM).
	FIGURE 5. Strychnine is an antagonist of human α9, α10, and α9α10 nAChRs expressed in X. laevis oocytes. Oocytes were injected with cRNA encoding either human α9 subunits or α10 subunits to form homomeric subtypes or with cRNA for α9 subunits and α10 subunits together (1:1) to form heteromeric α9α10 nAChRs. Oocytes were then incubated for 3–4 days prior to voltage-clamp electrophysiology. (A) Current traces from an oocyte, preincubated with saline containing 5 mM choline, expressing α9 nAChRs. The ACh-evoked currents after acute application of STR (20 μM) were 3 ± 3% (n = 5) of control values. (B) Current traces from an oocyte, preincubated with STR (20 μM), expressing α10 nAChRs; the ACh-evoked currents after acute application of STR (20 μM) were 52 ± 13% (n = 5) of control values. (C) Current traces from an oocyte, preincubated in saline, injected with cRNA for α9 and α10 nAChRs; the ACh-evoked currents after acute application of STR (20 μM) were 1.0 ± 0.5% (n = 5) of control values. Current traces are shown with the 30 s interpulse intervals reduced to 5 s for brevity, and the horizontal bars above the traces indicate a 5 min perfusion with saline containing STR. The “±” indicates the SD and “n” indicates the number of oocytes obtained from three donors.
	FIGURE 6. Choline enhances whereas STR inhibits functionality of human α9 nAChRs expressed in X. laevis oocytes. Oocytes were injected with cRNA encoding human α9 subunits and incubated for 3 days in frog saline or saline containing choline (5 mM) or STR (20 μM) and assessed by voltage-clamp electrophysiology for functional responses to acetylcholine (ACh; 100 μM). (A) A single 30 s current trace from a control oocyte incubated in frog saline. The oocytes responded to ACh with current amplitudes that were −9 ± 19 nA (n = 22). (B) Current amplitudes recorded from oocytes incubated with choline were −44 ± 47 nA (n = 25); a subset of this group of oocytes was incubated in frog saline containing STR (20 μM) for 24 h and reassessed for functional responses. The current amplitudes after exposure to STR were reduced to −2.1 ± 1.2 nA compared to −78 ± 44 nA (n = 5). (C) Similarly, oocytes incubated with STR for 3 days had ACh responses of −1.8 ± 1.2 nA (n = 17). (D) Scatter plot of the data for the experiments shown in (A–C). Current amplitudes from oocytes incubated with choline were significantly larger compared to saline controls. The current amplitude and duration scale-bars apply to all traces. The “±” and the error bars in (D) indicate SD. The “n” indicates the number of oocytes obtained from three donors.
	FIGURE 7. Currents evoked by acetylcholine (ACh; 1 mM) from oocytes expressing human α10 nAChRs are potently inhibited by α-Bgtx and α-Cbtx. X. laevis oocytes were injected with cRNA encoding human α10 subunits and incubated for 3–5 days in frog saline containing MLA (20 μM) or STR (20 μM) and assessed by voltage-clamp electrophysiology. (A) α-Bungarotoxin inhibited ACh-evoked responses with an IC50 of 21 (19–24) nM and the Hill slope was −1.0 (−1.1 to −0.9) (n = 5). (B) Current traces showing inhibition of ACh-evoked currents by α-Bgtx; the trace in red indicates a control response to ACh in the absence of α-Bgtx. (C) Graph showing the activities of select α-Ctxs, α-Cbtx, atropine, nicotine, MLA, and STR on human α10 nAChRs. The ACh responses in the presence of α-Ctx RgIA were 97 ± 8% (n = 5), 92 ± 9% (n = 9) for α-Ctx Vc1.1, and 97 ± 7% (n = 5) for α-Ctx PeIA. The responses in the presence of α-Cbtx were 3 ± 1% (n = 5). Responses in the presence of atropine, nicotine, MLA, and STR were 106 ± 7% (n = 7), 99 ± 8% (n = 5), 171 ± 71% (n = 8), and 203 ± 52% (n = 8), respectively. All ligands were tested at 10 μM. The parentheses indicate the 95% CI and the error bars in (A) and (C) indicate SD. The “n” indicates the number of oocytes obtained from nine donors. Oocytes in (A–B) were incubated with saline containing MLA (20 μM). In (C), all experiments were conducted on oocytes incubated with STR (20 μM) except those used for testing MLA and STR which were incubated in MLA (20 μM).
	FIGURE 8. Currents evoked by acetylcholine (ACh) from oocytes expressing human α9 or α9α10 nAChRs are inhibited by α-Ctx RgIA-5474, but those from oocytes expressing α10 nAChRs are not. (A) Traces showing inhibition of ACh-evoked (100 μM) currents by RgIA-5474 from an oocyte expressing α9 nAChRs. The responses in the presence of the peptide were 1.0 ± 0.4% (n = 5) of control values. (B) Traces from an oocyte expressing α10 nAChRs showing lack of inhibition by RgIA-5474 on ACh-evoked (1 mM) currents. The responses in the presence of the peptide were 100 ± 3% (n = 5) of control values. (C) Traces showing inhibition of ACh-evoked (100 μM) currents by RgIA-5474 from an oocyte expressing α9α10 nAChRs. The responses in the presence of the peptide were 3 ± 2% (n = 5) of control values. The horizontal bars above the current traces in (A–C) indicate perfusion with saline containing RgIA-5474 (50 nM). Current traces are shown with the 30 s interpulse intervals reduced to 5 s for brevity. The “±” indicates SD and “n” indicates the number of oocytes obtained from three donors. Oocytes in (A) were preincubated in saline containing choline (5 mM) and those in (B) with STR (20 μM) for 3 days.
	FIGURE 9. Acetylcholine (ACh) and choline, but not nicotine, evoke currents from oocytes expressing α10 nAChRs. X. laevis oocytes were injected with cRNA encoding human α10 subunits and incubated for 3–4 days in frog saline containing STR (20 μM) then assessed by voltage-clamp electrophysiology. (A) Concentration-response curve for acetylcholine, choline, and nicotine. The EC50 for activation of α10 nAChRs by ACh was 1.35 (1.15–1.58) mM and the Hill Slope was 1.1 (0.9–1.3) (n = 5). Choline was a partial agonist but evoked detectable currents only at 10 mM; the maximal response was 4 ± 2% (n = 5) of the calculated maximal response to ACh. Nicotine failed to induce detectable currents at concentrations up to 1 mM (n = 5). (B) Current traces evoked by 10 μM, 30 μM, 100 μM, 300 μM, 1 mM, 3 mM, and 10 mM ACh. (C) Current traces evoked by 100 μM, 1 mM, and 10 mM choline. (D) Current traces from an oocyte stimulated with 100 μM and 1 mM nicotine. All current traces in (B–D) were obtained from the same oocyte and are shown with the 35 s interpulse intervals reduced to 5 s for brevity. The current amplitude and time-scale bars apply to all traces in B-D. Values in parentheses indicate the 95% CI and the “±” indicates SD; “n” indicates the number of oocytes obtained from one donor.
	FIGURE 10. Acetylcholine-evoked currents from human homomeric α10 nAChRs desensitize faster relative to those from human α9α10 nAChRs. X. laevis oocytes were injected with cRNA encoding human α10 subunits and incubated in frog saline containing STR (20 μM) or with cRNAs for α9 plus α10 subunits, incubated in saline only, and subjected to voltage-clamp electrophysiology after 3 days. (A) Current traces from α10 nAChRs showing the response to a 15 s pulse of ACh in the presence of calcium (red) compared to barium (black). (B) The peak current amplitudes in response to ACh were −1,818 ± 1,329 nA (n = 5) in the presence of calcium and −1,430 ± 1,424 nA (n = 5) in the presence of barium. The responses decayed to −553 ± 396 nA or 31 ± 6% (n = 5) of peak amplitude at the end of the 15 s pulse of ACh in the presence of calcium. The responses decayed to −459 ± 375 nA or 35 ± 11% (n = 5) of peak amplitude at the end of the 15 s pulse of ACh in the presence of barium. (C) Current traces from α9α10 nAChRs showing the response to a 15 s pulse of ACh in the presence of calcium (red) compared to barium (black). (D) The peak current amplitudes in response to ACh were −484 ± 270 nA (n = 5) in the presence of calcium and −31 ± 40 nA (n = 5) in the presence of barium. The responses decayed to −154 ± 74 nA or 33 ± 4% (n = 5) of peak amplitude at the end of the 15 s pulse of ACh in the presence of calcium. The responses decayed to −23 ± 30 nA or 73 ± 8% (n = 5) of peak amplitude at the end of the 15 s pulse of ACh in the presence of barium. The inset shows expanded data for ACh-evoked currents obtained in the presence of barium. The “±” indicates SD and “n” indicates the number of oocytes obtained from two donors.

Akbar, Use of Strychnos nux-vomica (Azraqi) seeds in Unani system of medicine: role of detoxification. 2010, Pubmed

Akbar, Use of Strychnos nux-vomica (Azraqi) seeds in Unani system of medicine: role of detoxification. 2010, Pubmed
AlSharari, The α9α10 nicotinic acetylcholine receptors antagonist α-conotoxin RgIA reverses colitis signs in murine dextran sodium sulfate model. 2020, Pubmed
Alen, The cholinergic anti-inflammatory pathway in humans: State-of-the-art review and future directions. 2022, Pubmed
Azam, Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA. 2012, Pubmed , Xenbase
Baker, Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras. 2004, Pubmed , Xenbase
Barish, A transient calcium-dependent chloride current in the immature Xenopus oocyte. 1983, Pubmed , Xenbase
Bertrand, Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. 2008, Pubmed , Xenbase
Bschleipfer, Bladder outlet obstruction influences mRNA expression of cholinergic receptors on sensory neurons in mice. 2012, Pubmed
Bschleipfer, Expression and distribution of cholinergic receptors in the human urothelium. 2007, Pubmed
Dani, Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine. 2015, Pubmed
Elgoyhen, Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. 1994, Pubmed , Xenbase
Elgoyhen, alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. 2001, Pubmed , Xenbase
Ellison, Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR. 2006, Pubmed , Xenbase
Evans, Expression and functional characterisation of a human chimeric nicotinic receptor with alpha6beta4 properties. 2003, Pubmed , Xenbase
Filchakova, Functional expression of human α9* nicotinic acetylcholine receptors in X. laevis oocytes is dependent on the α9 subunit 5' UTR. 2013, Pubmed , Xenbase
Fucile, Ca2+ permeability through rat cloned alpha9-containing nicotinic acetylcholine receptors. 2006, Pubmed
Fujii, Expression and Function of the Cholinergic System in Immune Cells. 2017, Pubmed
Gajewiak, Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. 2021, Pubmed
George, Isoform-specific mechanisms of α3β4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1. 2017, Pubmed , Xenbase
Gu, Hair cell α9α10 nicotinic acetylcholine receptor functional expression regulated by ligand binding and deafness gene products. 2020, Pubmed
Gu, α6-Containing Nicotinic Acetylcholine Receptor Reconstitution Involves Mechanistically Distinct Accessory Components. 2019, Pubmed
Guo, Botany, Phytochemistry, Pharmacology and Toxicity of Strychnos nux-vomica L.: A Review. 2018, Pubmed
Haberberger, Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat. 2004, Pubmed
Henderson, Inside-out neuropharmacology of nicotinic drugs. 2015, Pubmed
Higgins, A desensitized form of neuronal acetylcholine receptor detected by 3H-nicotine binding on bovine adrenal chromaffin cells. 1988, Pubmed
Hone, PeIA-5466: A Novel Peptide Antagonist Containing Non-natural Amino Acids That Selectively Targets α3β2 Nicotinic Acetylcholine Receptors. 2019, Pubmed , Xenbase
Hone, Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the α6β4* subtype. 2012, Pubmed
Hone, Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists. 2020, Pubmed , Xenbase
Hone, Molecular determinants of α-conotoxin potency for inhibition of human and rat α6β4 nicotinic acetylcholine receptors. 2018, Pubmed , Xenbase
Ibañez-Tallon, Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. 2002, Pubmed , Xenbase
Indurthi, Presence of multiple binding sites on α9α10 nAChR receptors alludes to stoichiometric-dependent action of the α-conotoxin, Vc1.1. 2014, Pubmed , Xenbase
Jakubowski, Determining sequences and post-translational modifications of novel conotoxins in Conus victoriae using cDNA sequencing and mass spectrometry. 2004, Pubmed
Jensen, Elucidation of molecular impediments in the α6 subunit for in vitro expression of functional α6β4* nicotinic acetylcholine receptors. 2013, Pubmed , Xenbase
Johnson, alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors. 1995, Pubmed , Xenbase
Katz, High calcium permeability and calcium block of the alpha9 nicotinic acetylcholine receptor. 2000, Pubmed , Xenbase
Kawashima, Expression and function of genes encoding cholinergic components in murine immune cells. 2007, Pubmed
Kuryatov, Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses. 2000, Pubmed , Xenbase
Kurzen, Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. 2004, Pubmed
Kurzen, The non-neuronal cholinergic system of human skin. 2007, Pubmed
Lee, Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. 2010, Pubmed
Ley, Efficient expression of functional (α6β2)2β3 AChRs in Xenopus oocytes from free subunits using slightly modified α6 subunits. 2014, Pubmed , Xenbase
Lipovsek, Tracking the molecular evolution of calcium permeability in a nicotinic acetylcholine receptor. 2014, Pubmed , Xenbase
Lipovsek, The Hair Cell α9α10 Nicotinic Acetylcholine Receptor: Odd Cousin in an Old Family. 2021, Pubmed
Lu, Brucine: A Review of Phytochemistry, Pharmacology, and Toxicology. 2020, Pubmed
Lustig, Molecular cloning and mapping of the human nicotinic acetylcholine receptor alpha10 (CHRNA10). 2001, Pubmed
Marcovich, Distinct Evolutionary Trajectories of Neuronal and Hair Cell Nicotinic Acetylcholine Receptors. 2020, Pubmed
McIntosh, Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. 2004, Pubmed , Xenbase
McIntosh, A novel alpha-conotoxin, PeIA, cloned from Conus pergrandis, discriminates between rat alpha9alpha10 and alpha7 nicotinic cholinergic receptors. 2005, Pubmed , Xenbase
Mikulski, Nicotinic receptors on rat alveolar macrophages dampen ATP-induced increase in cytosolic calcium concentration. 2010, Pubmed
Miledi, Chloride current induced by injection of calcium into Xenopus oocytes. 1984, Pubmed , Xenbase
Mishra, Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors. 2010, Pubmed
Miwa, Lynx1 prototoxins: critical accessory proteins of neuronal nicotinic acetylcholine receptors. 2021, Pubmed
Moglie, Loss of Choline Agonism in the Inner Ear Hair Cell Nicotinic Acetylcholine Receptor Linked to the α10 Subunit. 2021, Pubmed
Morley, Commentary: Nicotinic Acetylcholine Receptor α9 and α10 Subunits Are Expressed in the Brain of Mice. 2018, Pubmed
Mucchietto, α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. 2018, Pubmed
Pacini, The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment. 2016, Pubmed
Papke, The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. 2015, Pubmed , Xenbase
Parker, Deletion of lynx1 reduces the function of α6* nicotinic receptors. 2017, Pubmed
Peng, Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes. 2004, Pubmed
Pérez, Molecular modeling of the alpha9alpha10 nicotinic acetylcholine receptor subtype. 2009, Pubmed
Pérez-Alvarez, Pharmacological characterization of native α7 nicotinic ACh receptors and their contribution to depolarization-elicited exocytosis in human chromaffin cells. 2012, Pubmed
Rau, Nicotinic AChR in subclassified capsaicin-sensitive and -insensitive nociceptors of the rat DRG. 2005, Pubmed
Richter, Phosphocholine - an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors. 2016, Pubmed , Xenbase
Rothlin, The alpha9 nicotinic acetylcholine receptor shares pharmacological properties with type A gamma-aminobutyric acid, glycine, and type 3 serotonin receptors. 1999, Pubmed , Xenbase
Satkunanathan, Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. 2005, Pubmed
Sgard, A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit. 2002, Pubmed , Xenbase
Srinivasan, Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. 2011, Pubmed
Tracey, Physiology and immunology of the cholinergic antiinflammatory pathway. 2007, Pubmed
Vincler, Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. 2006, Pubmed
Yu, Determination of the α-conotoxin Vc1.1 binding site on the α9α10 nicotinic acetylcholine receptor. 2013, Pubmed
Zakrzewicz, Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10. 2017, Pubmed
Zhang, Nicotine Evoked Currents in Human Primary Sensory Neurons. 2019, Pubmed
Zorrilla de San Martín, Ryanodine is a positive modulator of acetylcholine receptor gating in cochlear hair cells. 2007, Pubmed , Xenbase
Zouridakis, Crystal Structure of the Monomeric Extracellular Domain of α9 Nicotinic Receptor Subunit in Complex With α-Conotoxin RgIA: Molecular Dynamics Insights Into RgIA Binding to α9α10 Nicotinic Receptors. 2019, Pubmed
daCosta, Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation. 2011, Pubmed
del Barrio, Calcium signalling mediated through α7 and non-α7 nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release. 2011, Pubmed